| Literature DB >> 31618888 |
Nada Salhab1, Mona Alrukhaimi2, Jeroen Kooman3, Enrico Fiaccadori4, Harith Aljubori5, Rana Rizk6, Mirey Karavetian7.
Abstract
Intradialytic exercise (IDE) is not routinely prescribed in hemodialysis (HD) units despite its potential benefits on patients' outcomes. This study was the first in the United Arab Emirates to examine the effect of aerobic IDE on hyperphosphatemia, malnutrition, and other health outcomes among HD patients. Participants were chosen from the largest HD unit in Sharjah Emirate for a quasi-experimental intervention with pre and post evaluation. The study lasted for 12 months. Study parameters were collected at baseline, post intervention, and follow-up. The intervention included a moderate-intensity aerobic IDE of 45 min per HD session; intensity was assessed using the Borg Scale. Patients were educated on the importance of exercise. Study outcomes were serum phosphorus (P), malnutrition inflammation score (MIS), quality of life (QOL), and pertinent blood tests. Forty-one eligible consenting HD patients were included in the study. Results at follow-up showed a non-significant reduction in P (p = 0.06) in patients who were hyperphosphatemic at baseline, but not in the sample as whole. MIS did not deteriorate throughout the study (p = 0.97). IDE resulted in a non-significant increase in the QOL visual analogue scale (p = 0.34). To conclude, aerobic IDE for 45 min is safe and could be beneficial, especially for hyperphosphatemic patients.Entities:
Keywords: exercise; hemodialysis; hyperphosphatemia; phosphorus; quality of life
Mesh:
Substances:
Year: 2019 PMID: 31618888 PMCID: PMC6836201 DOI: 10.3390/nu11102464
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Attrition rate of the study.
Baseline Characteristics of patients (n = 30).
| Gender, Male | 15 (50) |
| Nationality | |
| Emirati | 5 (16.7) |
| Non-Emirati—Arab | 17 (56.7) |
| Non-Emirati—Other | 8 (26.7) |
| Primary Cause of CKD | |
| Diabetes | 16 (53.3) |
| Hypertension | 9 (30.0) |
| Nephritis | 3 (10.0) |
| Others | 2 (6.7) |
| HD Initiation | |
| <1 year | 8 (26.7) |
| 1–4 years | 11 (36.7) |
| >4 years | 11 (36.7) |
| Comorbidities † | |
| Diabetes | 16 (53.3) |
| Hypertension | 28 (93.3) |
| Cardiovascular disease | 4 (13.3) |
| Others | 8 (26.7) |
| Phosphorus ≥5.5 mg/dL | 15 (50) ‡ |
|
| |
| Age (years) | 48.87 ± 11.29 |
| Weight (Kg) | 66.76 ± 17.59 |
| BMI (Kg/m2) | 25.25 ± 6.71 |
† Percentages do not sum up due to multiple possible answers. ‡ Valid percentages are reported. Abbreviations: BMI: body mass index; CKD: chronic kidney disease; HD: hemodialysis.
Figure 2Patients’ adherence to the IDE program. * Moderate adherence: ≥60–80%; High Adherence: >80%.
Study outcomes of all patients (n = 30).
| Mean ± SD | Mean ± SD | Mean ± SD | ||
|---|---|---|---|---|
| P (mg/dL) | 5.78 ± 1.81 | 5.53 ± 2.14 | 5.52 ± 1.58 | 0.56/−4.50 |
| PTH (pmol/L) | 49.15 ± 31.65 | 54.58 ± 38.59 | 48.80 ± 35.61 | 0.52/−0.71 |
| Ca × P (mg2/dL2) | 48.96 ± 15.68 | 46.48 ± 16.48 | 47.16 ± 14.07 | 0.54/−3.68 |
| URR (%) | 72.93 ± 9.26 | 73.68 ± 12.38 | 74.38 ± 10.64 | 0.47/1.99 |
| Kt/V | 1.31 ± 0.1 | 1.29 ± 0.09 | 1.28 ± 0.06 | 0.17/−2.30 |
| HGB (g/dL) | 10.74 ± 1.45 | 11.1 ± 1.66 | 10.82 ± 1.59 | 0.52/0.74 |
| MIS | 8.2 ± 3.46 | 7.47 ± 3.39 | 6.67 ± 1.98 | 0.16/−18.66 |
| QOL-VAS | 63.03 ± 17.65 | 65.67 ± 19.64 | 68.66 ± 17.71 | 0.34/8.93 |
Abbreviations: % Δ: percentage change from baseline to follow-up; P: phosphorus; PTH: parathyroid hormone; Ca × P: calcium phosphorus byproduct; URR: urea reduction ration; Kt/V: dialysis adequacy; HGB: hemoglobin; MIS: malnutrition inflammation score; QOL-VAS: quality of life-visual analogue scale.
EuroQOL 5D-5L Questionnaire (n = 30).
| No Problem | Slight- | Severe | |||
|---|---|---|---|---|---|
| EQ-dimension | |||||
| Self-Care | Baseline | 26 (86.6) | 2 (6.7) | 2 (6.7) | |
| Post Intervention | 28 (93.3) | 2 (6.7) | 0 (0.0) | 0.368 | |
| Follow-up | 13 (43.3) | 13 (43.4) | 4 (13.3) | ||
| Daily Activities | Baseline | 18 (60.0) | 7 (23.3) | 5 (16.7) | |
| Post Intervention | 24 (80.0) | 6 (20.0) | 0 (0.0) | 0.070 | |
| Follow-up | 24 (80.0) | 5 (16.7) | 1 (3.3) | ||
| Anxiety/Depression | Baseline | 18 (60.0) | 7 (23.3) | 5 (16.7) | |
| Post Intervention | 13 (43.3) | 7 (23.3) | 10 (33.3) | 0.111 | |
| Follow-up | 20 (66.7) | 9 (30.0) | 1 (3.3) | ||
| Mobility | Baseline | 13 (43.3) | 9 (30.0) | 8 (26.7) | |
| Post Intervention | 15 (50.0) | 14 (46.7) | 1 (3.3) | 0.354 | |
| Follow-up | 8 (26.7) | 17 (56.7) | 5 (16.6) | ||
| Pain/Discomfort | Baseline | 11 (36.7) | 11 (36.7) | 8 (26.6) | |
| Post Intervention | 9 (30.0) | 14 (46.7) | 7 (23.3) | 0.781 | |
| Follow-up | 12 (40.0) | 13 (43.3) | 5 (16.7) |
Abbreviation: n: number of observations.